Report Highlights

How the ustekinumab market works: Supply Chain Explained

Ustekinumab is a fully human IgG1κ monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23. Its upstream production originates with Chinese Hamster Ovary (CHO) cell line development, which requires proprietary cell banks, growth media derived primarily from suppliers in the United States and Germany, and bioreactor systems manufactured by Sartorius, Cytiva, and Thermo Fisher Scientific. Large-scale fed-batch fermentation occurs in stainless-steel or single-use bioreactors of 2,000–20,000 litre capacity. Janssen operates primary biomanufacturing at its Leiden, Netherlands and Malvern, Pennsylvania facilities. Biosimilar manufacturers — including Alvotech in Iceland, Formycon in Germany, and Samsung Bioepis in South Korea — have constructed dedicated upstream trains for their own ustekinumab molecules, each requiring independent cell line characterisation and comparability studies against Stelara's reference product data package.

Downstream processing involves protein A affinity chromatography, viral inactivation, ultrafiltration, and sterile filtration — steps performed either at the same biomanufacturing campus or contract-transferred to CDMOs including Lonza and Boehringer Ingelheim Biopharmaceuticals. The final drug substance is then formulated into 90 mg/mL subcutaneous prefilled syringes or intravenous concentrate vials, filled under aseptic conditions, and cold-chain distributed at 2–8°C. Specialty distributors — AmerisourceBergen, McKesson, and Cardinal Health in North America; Alliance Healthcare in Europe — carry product to specialty pharmacies and hospital infusion centres. Margin concentration sits predominantly at the biomanufacturing stage for the originator and at the fill-finish and distribution stage for biosimilar entrants competing on net price rebates with pharmacy benefit managers.

Ustekinumab market dynamics

Ustekinumab pricing operates through a layered rebate architecture unique to the U.S. biologics market. Janssen historically offered gross-to-net discounts exceeding 50% on Stelara to retain formulary placement, a structure that biosimilar entrants are now exploiting by launching at list prices 30–45% below Stelara's wholesale acquisition cost while offering shallower rebate stacks — ultimately delivering lower net cost to payers. This dynamic is reshuffling buyer-seller power decisively in favour of pharmacy benefit managers and integrated delivery networks, which now hold formulary exclusivity contracts as their primary negotiating instrument. In Europe, reference pricing and national tendering systems in Germany, France, and the UK are compressing originator margins faster than in the United States, with the NHS awarding ustekinumab biosimilar framework contracts to Samsung Bioepis and Fresenius Kabi at prices representing 60–70% discounts to originator list.

Outside the U.S. and Western Europe, ustekinumab pricing is less commoditised. In Japan, the Pharmaceuticals and Medical Devices Agency has approved only one biosimilar to date, maintaining Janssen's Stelara at near-originator pricing through 2026. In Latin America and the Gulf Cooperation Council states, multi-year originator supply agreements dominate, as domestic biosimilar manufacturing capacity is absent and import registration timelines extend to 36 months. This geographic price fragmentation creates a two-tier market structure where originator revenue decay is concentrated in high-income markets while volume growth continues in emerging markets, partially offsetting the global revenue decline trajectory forecasted through 2034.

Growth drivers fuelling ustekinumab expansion

The primary growth driver for ustekinumab volume — even as originator revenue declines — is biosimilar-induced access expansion in price-sensitive markets. In India, Dr. Reddy's Laboratories has filed for ustekinumab biosimilar approval at a projected launch price below USD 800 per dose, versus Stelara's current Indian list price exceeding USD 3,500. This price compression activates a previously suppressed patient population: dermatologists and gastroenterologists in India currently undertreat moderate-to-severe Crohn's disease with biologics due to cost barriers. The supply chain mechanism is direct: lower API cost from domestic bioreactor capacity translates into increased dispensing volume through hospital procurement committees, which is the primary access point for biologics in India's public sector health system.

A second driver is label expansion activity and real-world evidence accumulation for ustekinumab in off-label indications — most notably primary sclerosing cholangitis and hidradenitis suppurativa — generating investigator-initiated demand at academic medical centres. This creates incremental specialty pharmacy pull-through independent of the formulary rebate negotiations that dominate mainstream psoriasis volumes. The third driver is the ongoing shift to subcutaneous self-administration formats. Prefilled autoinjector development by biosimilar manufacturers — specifically Alvotech's AVT04 device programme and Samsung Bioepis' SB17 — reduces healthcare resource utilisation per patient episode, lowering the total cost argument that payers use to resist biologic prescribing, thereby expanding addressable patient volumes across all approved indications.

Supply chain risks and market restraints

The most acute supply chain risk in the ustekinumab market is CHO cell culture media concentration. Four suppliers — Thermo Fisher Scientific, Merck KGaA, Sartorius Stedim, and Cytiva — collectively control over 80% of the specialised hydrolysate and chemically defined media used in monoclonal antibody upstream production. Any disruption to this upstream input layer — as demonstrated by Cytiva's resin allocation constraints during 2021–2022 — propagates directly into batch yield variability for biosimilar manufacturers who have less procurement leverage than Janssen. Alvotech, in particular, sources a significant share of its media from a single European supplier, creating a single-point procurement dependency that regulators have flagged in recent pre-approval inspections.

A second restraint is the regulatory pathway asymmetry between markets. The U.S. FDA's interchangeability designation — achieved by Amgen's Wezlana in 2023 — creates a two-tier biosimilar market where only interchangeable products can be pharmacy-substituted without physician intervention, concentrating formulary wins among the small number of entrants who have completed switching study programmes. Manufacturers who did not invest in interchangeability data — including several European market entrants — are structurally disadvantaged in the U.S. retail pharmacy channel and face a three-to-five year catch-up burden. Additionally, cold-chain logistics failures remain a persistent restraint in emerging markets: Brazil's ANVISA-regulated distribution network recorded five ustekinumab cold-chain excursion incidents in 2023, resulting in product quarantine and supply gaps at quaternary referral centres.

Where ustekinumab growth opportunities are emerging

The clearest opportunity in the ustekinumab supply chain is CDMO-based biosimilar manufacturing for smaller market entrants who lack internal bioreactor capacity. As the number of approved ustekinumab biosimilars globally reaches 15 or more by 2027, undercapitalised manufacturers in South Korea, India, and Eastern Europe will seek toll-manufacturing arrangements for both drug substance and fill-finish operations. CDMOs positioned in this space — specifically Samsung Biologics and WuXi Biologics — capture margin at the processing stage rather than competing on product differentiation. The value concentration here sits firmly in fill-finish and serialisation, where track-and-trace compliance requirements under the U.S. Drug Supply Chain Security Act and EU Falsified Medicines Directive create high switching costs for biosimilar sponsors.

A second opportunity lies in combination pack and device innovation. Janssen is investing in co-packaging Stelara with digital adherence tools to differentiate the originator in markets where biosimilar price parity is unavoidable. For biosimilar manufacturers, the autoinjector device supply chain — sourced primarily from Owen Mumford, Ypsomed, and Becton Dickinson — represents a value-add layer that commands a meaningful premium over vial presentations. Biosimilar sponsors who integrate autoinjector supply agreements with their fill-finish contracts by 2026 will capture the growing preference for self-administration in dermatology and gastroenterology clinics. The third emerging opportunity is ustekinumab lifecycle management in paediatric formulations: no approved paediatric prefilled syringe currently exists for doses below 45 mg, and the first entrant to achieve this will access an underserved segment with protected orphan-drug-equivalent market exclusivity in the EU.

Market at a Glance

Regional supply and demand map

On the supply side, biomanufacturing for ustekinumab is concentrated in five primary geographies. Janssen operates originator production in Leiden, Netherlands and Malvern, Pennsylvania. South Korea — through Samsung Bioepis and its parent Samsung Biologics — is the most significant biosimilar manufacturing hub, with dedicated 15,000-litre bioreactor trains validated specifically for ustekinumab drug substance. Iceland hosts Alvotech's vertically integrated facility, while Germany accommodates Formycon's outsourced production via Rentschler Biotechnologie. India is the emerging upstream geography, with Dr. Reddy's Laboratories and Biocon both investing in dedicated mAb bioreactor capacity to serve domestic and export markets simultaneously.

On the demand side, North America accounts for over 55% of global ustekinumab revenue in 2024, driven by the U.S. specialty pharmacy channel and high originator list prices now transitioning to biosimilar net pricing. Western Europe represents the second-largest demand region, with the UK, Germany, and France collectively consuming the largest biosimilar volumes outside the U.S. following national tendering programme awards. Japan and Australia constitute mid-tier demand markets with slower biosimilar penetration due to regulatory conservatism. The most significant trade flow imbalance exists between South Korea — a net exporter of drug substance — and the United States, where all biosimilar manufacturers must satisfy FDA site-specific approval requirements, creating a regulatory bottleneck that constrains how quickly Korean-manufactured drug substance can be converted into U.S.-labelled finished product.

Leading Market Participants

• Janssen Biotech (Johnson & Johnson)
• Amgen
• Samsung Bioepis
• Alvotech
• Fresenius Kabi
• Teva Pharmaceutical Industries
• Formycon
• Dr. Reddy's Laboratories
• Biocon Biologics
• Celltrion

Long-term ustekinumab outlook

By 2034, the ustekinumab supply chain will have undergone structural consolidation. The current phase of parallel biosimilar entry — with 10 or more products competing simultaneously in the U.S. — will compress margins to a point where manufacturers without integrated bioreactor and fill-finish capabilities exit the market. The surviving supply chain will resemble the adalimumab biosimilar market post-2023: two or three large-volume biosimilar manufacturers — most likely Samsung Bioepis, Amgen, and one Indian entrant — supplying the bulk of global demand under long-term payer contracts. Janssen's Stelara will persist as a niche premium product in markets with biosimilar-naïve patient populations and in hospital formularies that have not activated substitution policies, but its global revenue share will decline below 20% of the total ustekinumab market by 2032.

The most valuable supply chain positions in 2034 will be fill-finish capacity ownership and device supply integration. As drug substance becomes increasingly commoditised — with CHO-based production costs declining toward USD 50–80 per gram through process intensification — the differentiated margin will sit in sterile filling suites, autoinjector assembly, and secondary packaging with digital authentication features. CDMOs with validated prefilled syringe lines and established 503B outsourcing facility status in the U.S. will command premium tolling rates. Samsung Biologics, Lonza, and Boehringer Ingelheim Biopharmaceuticals are best positioned to capture this value. Biosimilar sponsors with proprietary autoinjector device partnerships — specifically Alvotech with its Stelara-matched device programme — hold the most defensible commercial positions against further price commoditisation in the self-administration segment.

Market Segmentation

By Product Type

• Originator (Stelara)
• Biosimilar — Approved
• Biosimilar — Pipeline

By Formulation and Presentation

• Subcutaneous Prefilled Syringe
• Intravenous Concentrate Vial
• Subcutaneous Autoinjector

By Indication

• Plaque Psoriasis
• Psoriatic Arthritis
• Crohn's Disease
• Ulcerative Colitis
• Off-Label Indications

By Distribution Channel

• Specialty Pharmacy
• Hospital Infusion Centre
• Retail Pharmacy
• Direct-to-Patient Mail Order
• Government Procurement Programme

Frequently Asked Questions

Q1. Where is ustekinumab drug substance primarily manufactured globally ▼

Originator drug substance is produced by Janssen at facilities in Leiden, Netherlands and Malvern, Pennsylvania. Biosimilar drug substance production is concentrated in South Korea, Iceland, Germany, and increasingly India.

Q2. How does biosimilar interchangeability affect the ustekinumab distribution channel ▼

Interchangeable biosimilars — such as Amgen's Wezlana — can be substituted at the pharmacy level without physician authorisation, dramatically increasing their penetration in the retail specialty pharmacy channel. Non-interchangeable biosimilars must be prescribed by name, limiting their formulary uptake to physician-driven switches only.

Q3. What cold-chain requirements apply to ustekinumab throughout the supply chain ▼

Ustekinumab requires continuous refrigeration at 2–8°C from bulk drug substance shipment through final patient dispensing. Any temperature excursion outside this range triggers mandatory quarantine and stability investigation under FDA and EMA good distribution practice regulations.

Q4. How do pharmacy benefit manager formulary decisions affect ustekinumab trade flows ▼

PBMs including CVS Caremark and Express Scripts determine which ustekinumab products are covered on their national formularies, directly controlling the volume routed to specific biosimilar manufacturers through specialty pharmacy networks. A single exclusive formulary award from a major PBM can represent 8–12% of total U.S. biosimilar volume for a given entrant.

Q5. What regulatory pathway differences exist between the U.S. and EU for ustekinumab biosimilars ▼

The FDA requires interchangeability switching studies on top of standard biosimilarity data, creating an additional clinical and regulatory burden absent in the EMA pathway. The EMA's extrapolation principles allow a single biosimilarity dossier to cover all originator indications without indication-specific clinical trials, accelerating European approval timelines relative to the United States.